Kattula Rao Vinay Rajan1*, Pasam Sathish Sreenivas2, Pilla Sree Surya Durga Devi1, Penugonda Vineela1, Haritha Allu1, Prasad Reddy M1, Ravisankar Pasam3
1Doctor of Pharmacy, GIET School of Pharmacy, Rajahmundry, A.P, India
2Department of Medicine, Rangaraya Medical College, Kakinada, A.P, India
3Konaseema Institute of Medical Sciences and Research Foundation, Amalapuram, A.P, India
Whipple’s disease is a rare, multi-systemic chronic infectious disease that preferentially affects middle-aged white men. In 1907 George Whipple first reported it and named this disease “intestinal lipodystrophy”. It is a rare condition, estimated incident rate is 1 per 1000000 populations per year. The causative agent is “Tropheryma whipplei”. This name originated from Greek word “trophe” (nourishment), “eryma” (barrier) and from the name of the person who first reported the disease “George Hoyt Whiplle. It is a systemic disease, mainly affects the gastro intestinal system, and also all the other systems in the body. The classic clinical manifestations are arthralgia, weight loss, diarrhoea, abdominal discomfort, and also include amnesia, dementia, insomnia and dyspnoea. Diagnosis is made generally by small bowel biopsy that reveal characteristic foamy macrophages that are Periodic acid-schiff stain positive. Currently no anystandard treatment regimen approved for Whipple’s disease.
Keywords: Whipple’s disease, Tropheryma whipplei, intestinal lipodystrophy, Periodic acid- Schiff.